News

AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. AstraZeneca PLC (NASDAQ:AZN ...
AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...
AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...
AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...
Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...
AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...
The decline in the company's share price came as its shares traded ex-date following the announcement of a ₹32 per share ...
AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...
AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...
AstraZeneca’s contract to supply the UK with 100 million Covid-19 vaccine doses commits it to making “best reasonable efforts,” the same language used in its deal with the European Union ...